LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

Biogen Inc

Slēgts

SektorsVeselības aprūpe

140.29 0.24

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

140.04

Max

141.94

Galvenie mērījumi

By Trading Economics

Ienākumi

394M

635M

Pārdošana

215M

2.6B

P/E

Sektora vidējais

12.653

35.733

EPS

3.02

Peļņas marža

23.995

Darbinieki

7,605

EBITDA

457M

1B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+20.72% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 29. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

442M

19B

Iepriekšējā atvēršanas cena

140.05

Iepriekšējā slēgšanas cena

140.29

Ziņu noskaņojums

By Acuity

31%

69%

92 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Biogen Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 6. sept. 09:30 UTC

Iegādes, apvienošanās, pārņemšana

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

2025. g. 6. sept. 08:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 5. sept. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 5. sept. 20:37 UTC

Iegādes, apvienošanās, pārņemšana

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

2025. g. 5. sept. 20:37 UTC

Iegādes, apvienošanās, pārņemšana

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

2025. g. 5. sept. 20:36 UTC

Iegādes, apvienošanās, pārņemšana

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

2025. g. 5. sept. 20:36 UTC

Iegādes, apvienošanās, pārņemšana

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

2025. g. 5. sept. 20:33 UTC

Iegādes, apvienošanās, pārņemšana

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

2025. g. 5. sept. 20:33 UTC

Iegādes, apvienošanās, pārņemšana

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

2025. g. 5. sept. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

2025. g. 5. sept. 20:20 UTC

Peļņas

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

2025. g. 5. sept. 19:23 UTC

Tirgus saruna

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

2025. g. 5. sept. 19:22 UTC

Peļņas

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

2025. g. 5. sept. 19:17 UTC

Tirgus saruna

U.S. Natural Gas Snaps Winning Streak -- Market Talk

2025. g. 5. sept. 18:59 UTC

Peļņas

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

2025. g. 5. sept. 18:35 UTC

Tirgus saruna

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

2025. g. 5. sept. 17:25 UTC

Tirgus saruna

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

2025. g. 5. sept. 17:20 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

2025. g. 5. sept. 17:17 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 5. sept. 17:17 UTC

Tirgus saruna

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

2025. g. 5. sept. 17:03 UTC

Tirgus saruna

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

2025. g. 5. sept. 16:39 UTC

Iegādes, apvienošanās, pārņemšana

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

2025. g. 5. sept. 16:39 UTC

Iegādes, apvienošanās, pārņemšana

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

2025. g. 5. sept. 16:39 UTC

Iegādes, apvienošanās, pārņemšana

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

2025. g. 5. sept. 16:39 UTC

Iegādes, apvienošanās, pārņemšana

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

2025. g. 5. sept. 16:37 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2025. g. 5. sept. 16:37 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Energy Roundup: Market Talk

2025. g. 5. sept. 16:37 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

2025. g. 5. sept. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 5. sept. 16:16 UTC

Peļņas

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Biogen Inc Prognoze

Cenas mērķis

By TipRanks

20.72% augšup

Prognoze 12 mēnešiem

Vidējais 169.81 USD  20.72%

Augstākais 260 USD

Zemākais 118 USD

Pamatojoties uz 26 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Biogen Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

26 ratings

12

Pirkt

14

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

118.15 / 121.17Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

92 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat